This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The rate of early mortality did not change significantly over the study period. It was 5.9% in the pre-intervention period and 6.0% in the post-intervention period.
The rate of early re-sternotomies did not differ statistically between the groups. It was 6.6% in the pre-intervention period and 5.5% in the post-intervention period, (p=0.384).
The EuroSCORE exhibited a significant increase, from 5.0 (+/-3.3) in the pre-intervention period to 5.4 (+/-3.1) in the post-intervention period, (p=0.006). The authors stated that this might indicate an increase in morbidity.
Clinical conclusions
The effectiveness analysis showed that clinical end points were stable after the implementation of the bedside coagulation management system.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and were not combined with the costs. In effect, a cost-consequences analysis was carried out.
Direct costs
The perspective of the analysis was unclear, but it might have been that of the hospital. The categories of costs included in the study were those associated with red blood cells, platelet concentrate, fresh frozen plasma, pooled coagulation concentrate, fibrinogen, rfactor VIIa, factor XIII, aprotinin, antithrombin III and desmopressin. The cost of the ROTEM device (rental cost and cost per analysis) was included only in the post-intervention group. The unit costs were presented separately from the quantities of resources used. The source of the costs was not reported although it might have been the authors' institution. The resource use data were derived retrospectively from the sample of patients included in the analysis of effectiveness. Discounting was not relevant as short-term costs were evaluated. The price year was not reported.
Statistical analysis of costs
Conventional statistical tests of the costs and quantities were performed.
Indirect Costs
Productivity costs were not considered.
Currency Euros (EUR).
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Sensitivity analysis
No sensitivity analyses were performed.
Estimated benefits used in the economic analysis
See the ,Effectiveness Results-section.
Cost results
The use of ROTEM led to a statistically significant reduction in the use of platelet concentrate, pooled coagulation concentrate, rfactor VIIa, factor XIII, aprotinin, antithrombin III and desmopressin.
The cost analysis therefore showed that, over the study period, the cumulative average monthly costs fell from EUR 125,828 in the pre-intervention period to EUR 55,925 in the post-intervention period.
The costs of all blood products decreased from EUR 66,000 to EUR 45,000 (-32%). Coagulation factor average monthly costs decreased from EUR 60,000 to EUR 30,000 (-50%) yielding combined savings of 44%. In contrast, the average monthly cost for the bedside coagulation management system amounted to EUR 1,580.
Synthesis of costs and benefits
A synthesis of the costs and benefits was not relevant as a cost-consequences analysis was performed.
Authors' conclusions
The implementation of a bedside coagulation management system in patients undergoing cardiac surgery led to a significant reduction in the total costs of care and to a non significant reduction in the number of re-sternotomies, without affecting early mortality.
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparators was clear in that the new intervention was compared with the pattern of care delivered before its implementation. A detailed description of ROTEM was given. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The clinical data were derived from a retrospective study, which is usually associated with a limited internal validity. Further, the two groups of patients were not studied concurrently, which means that the impact of factors other than the study intervention might have had an impact on the clinical end points. The authors did not take the potential impact of time-and organisation-related confounding factors into consideration. However, the two patients groups were similar at baseline in terms of their demographic and clinical characteristics. Although a large sample of patients was considered, no formal justification for the size of the sample was provided and power calculations were not performed. Another drawback of the analysis was the fact that patients were identified at a single institution, which may not have been representative of other medical centres. This casts some doubt on the degree to which the study sample was representative of the patient population. These issues should be considered when judging the internal validity of the analysis.
